AstraZeneca Advanced Phase 3 Trial for Oral Weight Loss Drug
The drug candidate elecoglipron has moved into late-stage testing for adults managing obesity and type 2 diabetes.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical firms to prioritize long-term patient health when developing new obesity treatments?
AstraZeneca has officially initiated a global Phase 3 clinical program for the oral medication elecoglipron, a milestone that triggered a $50 million payment to its partner, Eccogene. The move marks a critical step forward in testing the drug as a potential treatment option for adults with obesity or type 2 diabetes.
Why it matters
As the demand for accessible weight management and blood sugar control grows, this development signals progress in moving potentially effective oral alternatives toward clinical availability. This transition to late-stage testing means larger studies are underway to confirm the medication's long-term safety and efficacy profile.
In Phase 2b VISTA and SOLSTICE trials, elecoglipron demonstrated an 11.8% reduction in body weight at 36 weeks and a 1.9% decrease in HbA1c at 26 weeks among participants. These findings are preliminary, as the large-scale Phase 3 Embold and Eluminate studies are now designed to confirm these initial efficacy outcomes.
The players
AstraZeneca
A global biopharmaceutical company focusing on oncology, rare diseases, and cardiometabolic therapies.
Eccogene
A biotechnology company focused on discovering and developing small molecule therapies for metabolic and immune-related diseases.
The details
Elecoglipron is a small molecule designed to act as a GLP-1 receptor agonist that can be taken orally once daily. By mimicking the GLP-1 hormone, the molecule works to regulate appetite and improve insulin sensitivity in patients with metabolic conditions. The current global Phase 3 program aims to validate these effects across the Embold and Eluminate trial series.
Timeline
November 2023: Eccogene entered a licensing agreement with AstraZeneca.
September 29, 2026: Eccogene announced the receipt of a $50 million milestone payment.
Health Landscape
This program follows a pattern set by the development pipeline for oral GLP-1 receptor agonists to reduce reliance on injectable formulations. It highlights the industry-wide effort to translate the success of injectable metabolic treatments into more convenient, pill-based daily options.
While this drug is not yet available to the public, these findings underscore the potential for non-injectable treatment options in the future. If you are currently managing obesity or type 2 diabetes, you may want to discuss with your doctor whether your current care plan aligns with emerging clinical trial criteria.
The takeaway
The move to Phase 3 testing is a standard, essential step in gathering the data required for potential regulatory approval. Continue to monitor for future clinical study results, and consult with your physician to ensure your current metabolic health goals are being met with established therapies.
Further reading
For more on emerging therapies, explore the latest research in our Diabetes section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical firms to prioritize long-term patient health when developing new obesity treatments?
